Daily Cosmetic Research Analysis
Across cosmetic and reconstructive contexts, one large cohort shows oral contraceptives need not be stopped before reduction mammoplasty, a national snapshot study demonstrates neoadjuvant therapy enables breast-conserving surgery and axillary de-escalation with cosmetic benefits, and a mechanistic zebrafish study links a common cosmetic preservative (benzalkonium chloride) to sensory neurotoxicity via oxidative stress.
Summary
Across cosmetic and reconstructive contexts, one large cohort shows oral contraceptives need not be stopped before reduction mammoplasty, a national snapshot study demonstrates neoadjuvant therapy enables breast-conserving surgery and axillary de-escalation with cosmetic benefits, and a mechanistic zebrafish study links a common cosmetic preservative (benzalkonium chloride) to sensory neurotoxicity via oxidative stress.
Research Themes
- Perioperative management in aesthetic/plastic surgery
- Oncologic downstaging to optimize cosmetic outcomes
- Cosmetic ingredient safety and sensory neurotoxicity mechanisms
Selected Articles
1. Oral contraceptive pills and reduction mammoplasty: A retrospective cohort analysis.
In a propensity-matched cohort of 17,052 patients undergoing reduction mammoplasty, continuing oral contraceptives was not associated with higher embolism/thrombosis and was linked to lower hematoma/hemorrhage compared with controls. No differences were observed in pain, ptosis, fat necrosis, or deformity within 6 months.
Impact: This large, matched cohort directly informs perioperative management by challenging the common practice of stopping oral contraceptives before breast reduction surgery.
Clinical Implications: Routine discontinuation of OCPs before reduction mammoplasty is unlikely to improve outcomes; decisions should be individualized considering overall VTE risk and patient preferences.
Key Findings
- After propensity matching (n=8,526 per group), controls had a 1.36-fold higher hematoma/hemorrhage risk (2.3% vs 1.7%; 95% CI 1.10–1.68; p<0.01).
- OCP use did not increase embolism/thrombosis (0.38% vs 0.41%; RR 0.91; 95% CI 0.57–1.48; p=0.71).
- No significant differences in mastodynia (p=0.10), ptosis (p=0.15), fat necrosis (p=0.54), or deformity/disproportion (p=0.32).
Methodological Strengths
- Large propensity score–matched cohorts with predefined postoperative outcomes within 6 months
- Focused evaluation of both bleeding and thromboembolic complications relevant to OCP use
Limitations
- Retrospective design with potential residual confounding
- Lack of granular data on OCP formulation, dose, and duration
Future Directions: Prospective studies stratifying by estrogen dose and baseline VTE risk; evaluation of perioperative pathways that safely avoid OCP discontinuation.
BACKGROUND: Oral contraceptive pills (OCPs) are commonly utilized by women aged 15-40 years. Despite being associated with an increased risk of thromboembolism, their potential impact on surgical outcomes, particularly in reduction mammoplasty, remains unknown. We aimed to explore the association between OCP use and outcomes following reduction mammoplasty. METHODS: A retrospective cohort study was conducted. An OCP group was defined by those who were taking oral contraceptive pills at the time of reduction mammoplasty and those in control group were not taking OCPs. Propensity score matching was carried out for age, race, previous delivery, and body mass index. Mastodynia, ptosis, fat necrosis, deformity/disproportion of the breast, hematoma/hemorrhage, and embolism/thrombosis that occurred within 6 months of surgery were documented. RESULTS: Each cohort contained 8526 patients with a mean age of 31.7 years (SD: 11.5 years). Controls exhibited a 1.36-fold higher likelihood of hematoma/hemorrhage, with 195 (2.3%) cases. Controls experiencing the complication were compared to 143 (1.7%) individuals on OCPs (CI:1.10-1.68; p<0.01). However, the OCP group did not demonstrate an increased risk for developing an embolism or thrombosis, with 32 (.38%) experiencing the complication compared to 35 (.41%) controls (RR=.91; CI:.57-1.48; p=.71). No statistical difference was found in mastodynia (p=.10), ptosis (p=.15), fat necrosis (p=.54), or deformity or disproportion/reconstructed breast (p=.32). CONCLUSION: Discontinuation of OCPs prior to reduction mammoplasty would not offer any discernible advantages in postoperative outcomes. The decision to continue or discontinue OCPs before reduction mammoplasty should be based on patient-specific factors, rather than on reducing the risks associated with the procedure.
2. Developmental exposure to benzalkonium chloride induces defects in mechanosensory hair cells and nociceptive responses in zebrafish.
Developmental BKC exposure in zebrafish caused dose-dependent defects in sensory hair cells, reduced startle responses, and increased nociception, accompanied by oxidative stress and pro-inflammatory gene upregulation. Altered expression of pou4f3 and tmc2a/b suggests disrupted hair-cell maturation and mechanotransduction as a mechanistic basis.
Impact: Identifies a mechanistic link between a ubiquitous cosmetic/pharmaceutical preservative and sensory neurotoxicity, advancing toxicology and public health risk assessment.
Clinical Implications: While preclinical, these data support re-evaluating BKC concentrations and monitoring for sensory adverse effects in high-exposure settings; they motivate safer preservative strategies.
Key Findings
- Embryonic exposure to 0.72–2.24 mg/L BKC impaired mechanosensory hair cells, reduced startle responses, and increased nociceptive sensitivity in a dose-dependent manner.
- BKC induced oxidative stress with increased ROS, decreased antioxidant enzyme activity, and altered redox gene expression.
- Inflammatory/pain-related genes (tnfa, il1b, cox2, bdnf, trpa1b) were upregulated.
- Hair-cell markers showed increased pou4f3 and decreased tmc2a/tmc2b, indicating disrupted differentiation and mechanotransduction.
Methodological Strengths
- In vivo vertebrate model with multiple exposure doses and convergent behavioral, cellular, and molecular readouts
- Mechanistic gene-expression profiling linking oxidative stress to sensory phenotypes
Limitations
- Preclinical zebrafish model limits direct human translational inference
- Environmental relevance of exposure levels and lack of mammalian validation
Future Directions: Validate findings in mammalian models, define human-relevant exposure thresholds, and test mitigation (e.g., antioxidant rescue) to inform safer preservative use.
Sensory neurotoxicity involves damage to the sensory nerves, often resulting from exposure to chemicals, medications, toxins, infections, or neurological disorders. Benzalkonium chloride (BKC) is a widely used quaternary ammonium compound with antiseptic properties, commonly present in pharmaceuticals, household products, and cosmetics. While the potential neurotoxicity of BKC has been previously explored in ocular and nasal epithelia, its impact on other sensory systems and the underlying mechanisms remain largely unclear. In this study, we used zebrafish (Danio rerio) embryos to assess the developmental neurotoxicity of BKC. Embryonic exposure to 0.72, 1.28, and 2.24 mg/L BKC led to dose-dependent impairments in mechanosensory hair cells, reduced startle responses, and heightened nociceptive sensitivity upon noxious stimulation. BKC exposure induced pronounced oxidative stress, evidenced by increased reactive oxygen species levels, reduced antioxidant enzyme activity, and altered expression of redox-regulating genes. Moreover, BKC significantly upregulated inflammatory and pain-associated genes, including tnfa, il1b, cox2, bdnf, and trpa1b. Expression profiling of hair cell differentiation markers revealed increased pou4f3 and decreased tmc2a/tmc2b, suggesting that BKC disrupts both terminal differentiation and mechanotransduction processes in sensory hair cells. Collectively, these findings uncover a novel mechanistic link between oxidative stress, impaired hair-cell maturation, and sensory dysfunction, offering new insights into the mechanisms underlying BKC-induced sensory neurotoxicity. This study emphasizes the ecological and toxicological relevance of quaternary ammonium compounds in aquatic environments.
3. National Breast Cancer Surgery Snapshot Study: Breast Cancer Surgery after Neoadjuvant Systemic Therapy in Primary Breast Cancer (MANS Study).
In a 70-center prospective snapshot (n=467), NST was mainly used for TN/HER2+ subtypes and axillary downstaging. Nearly half of patients initially planned for mastectomy converted to breast-conserving surgery, and 87% of cN+ patients avoided ALND, supporting de-escalation with potential cosmetic benefits.
Impact: Provides real-time, multicenter evidence that NST facilitates breast-conserving surgery and omission of ALND, quantifying practice patterns that improve cosmetic outcomes and reduce morbidity.
Clinical Implications: Encourages consideration of NST to enable BCS and axillary de-escalation, especially in TN and HER2+ disease, informing surgical planning and patient counseling on cosmetic outcomes.
Key Findings
- Among 467 NST patients, main reasons were axillary down-staging (26%), triple-negative (25%), and HER2+ (25%).
- Of 210 initially planned mastectomies, 99 (47%) converted to breast-conserving surgery; triple-negative tumors had the highest conversion (68%).
- Among mastectomy patients, 30% achieved breast pCR; 87% of cN+ patients converted from ALND to axillary-sparing surgery.
Methodological Strengths
- Prospective, multicenter snapshot capturing indications and surgical plans versus actual outcomes
- Granular pre- and post-NST surgical intent documentation enabling conversion rate estimates
Limitations
- Short 2-month inclusion window may limit generalizability and introduces selection bias
- Lack of long-term oncologic and patient-reported outcomes
Future Directions: Link surgical de-escalation to locoregional control, survival, and patient-reported cosmetic outcomes; refine criteria for omitting ALND.
INTRODUCTION: The use of neoadjuvant systemic therapy (NST) in primary breast cancer has increased worldwide. This study provides real-time data of the reasons and variation in NST, conversion rate of mastectomy to BCS and conversion rate of ALND to radiation or omission of axillary treatment. METHODS: This is a Breast Cancer Surgery Snapshot study, multicenter prospective cross-sectional study in 70 breast cancer hospitals in the Netherlands. For 2 months the reason for NST is registered with patient- and tumor characteristics. The expectation of the surgical procedure in breast and axilla before and after NST is noted and the actual surgical outcome after NST is registered. RESULTS: Four hundred sixty seven patients receiving NST were registered. The 3 main reasons for NST were in 26% axillary down-staging, 25% a triple negative (TN) tumor and 25% HER2+. Before NST, 219 patients (47%) were eligible for BCS. In 210 patients (45%) initially assigned to receive a mastectomy, 99 patients (47%) underwent BCS. Triple negativity had the highest conversion rate with 68%. Of all mastectomy patients, 30% showed a pCR of the breast. Axillary conversion from ALND to axillary sparing surgery was achieved in 87% cN+ patients. CONCLUSION: In the Netherlands the main reasons for NST were subtype (triple negative, HER2+) and axillary down staging. Additional reasons for NST focused more on down staging to convert to BCS and improve cosmetic outcomes. Real time data showed that NST lead to very high conversion rates from mastectomy to BCS as well as high rates of omission of ALND after NST.